No profile data available.
Spero Therapeutics, Inc. (SPRO) is a healthcare company in the antibacterial pharmaceuticals industry, based in Cambridge, United States, with about 25 full-time employees.
It reported revenue of $27.40 million for fiscal year 2024, down 71.7% from fiscal year 2023, and net income of -$68.57 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $3.05 million, down 61.0% from a year before. Its market capitalization was $69.88 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Spero Therapeutics reported $27.40 million in revenue for fiscal year 2024, down 71.7% from $96.74 million in fiscal year 2023. In Q3 2025 revenue was $3.05 million.
$69.88 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antibacterial pharmaceuticals) include BGM Group Ltd. (BGM), Armata Pharmaceuticals, Inc. (ARMP), PolyPid Ltd. (PYPD), China Pharma Holdings, Inc. (CPHI).